Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). A growing body of research underscores ...

Quest Diagnostics DGX company, Haystack Oncology, recently announced a research collaboration with the Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive ...

Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid ...

DNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes. In an interview with Targeted Oncology, Rutika Mehta, MD, ...

A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream ...